Evidence map›Paper›PMID 35137572›Full record

Trial reportBrain and behavior2022

Clinical evaluation of switching from immediate-release to prolonged-release lithium in bipolar patients, poorly tolerant to lithium immediate-release treatment: A randomized clinical trial.

Federica Pelacchi, Liliana Dell'Osso, Emi Bondi, Mario Amore, Andrea Fagiolini, Paolo Iazzetta, Daniela Pierucci, Manuela Gorini, Elisa Quarchioni, Alessandro Comandini and 4 more

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Brain and behavior, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 36 citations in OpenAlex.

  1. Trial
  2. Article
  3. Observational
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 2 countries.

Federica PelacchiGlobal Medical Department, Angelini Pharma S.p.A., Rome, Italy.
Liliana Dell'OssoDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Emi BondiPsychiatric Service Diagnosis and Care, Papa Giovanni XXIII Hospital, Bergamo, Italy.
Mario AmoreInstitute of Rehabilitation and Care for Scientific Character San Martino Polyclinic Hospital, University Psychiatric Clinic, Genova, Italy.
Andrea FagioliniPsychiatry, University-Hospital of Siena, Siena, Italy.
Paolo IazzettaFunctional Unit Mental Health Adults, San Giovanni di Dio Hospital, Orbetello-Grosseto, Italy.
Daniela PierucciGlobal Medical Department, Angelini Pharma S.p.A., Rome, Italy.
Manuela GoriniGlobal Medical Department, Angelini Pharma S.p.A., Rome, Italy.
Elisa QuarchioniGlobal Medical Department, Angelini Pharma S.p.A., Rome, Italy.
Alessandro ComandiniGlobal Medical Department, Angelini Pharma S.p.A., Rome, Italy.
Enrica SalvatoriGlobal Medical Department, Angelini Pharma S.p.A., Rome, Italy.
Agnese CattaneoGlobal Medical Department, Angelini Pharma S.p.A., Rome, Italy.
Maurizio PompiliComplex Operational Unit Psychiatry, Sant'Andrea University-Hospital, University of Rome La Sapienza, Rome, Italy.
SALT Study Group
Angelini Pharma (Italy) · ITAzienda Ospedaliera Sant'Andrea · ITMartin University · USNuovo Ospedale San Giovanni di Dio · ITOspedale Papa Giovanni XXIII · ITUniversity of Pisa · ITUniversity of Siena · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe effect of switching from lithium immediate release (Li-IR) to lithium prolonged release (Li-PR) on lithium-induced tremor after 1 and 12 weeks of treatment was evaluated in a randomized, multicenter, open trial, in bipolar patients from the participating sites with a tremor severity ≥2 (Udvalg for Kliniske Undersøgelser [UKU] rating scale) despite optimal lithium titration.

methodsThe primary endpoint was the evaluation of tremor by means of the UKU scale after 1 week of treatment. Secondary endpoints included manic Young Mania Rating Scale (YMRS) and depressive symptoms (Montgomery-Asberg Depression Rating Scale), a global assessment of the patient's status (Clinical Global Impression), polyuria/polydipsia (UKU item 3.8) and patient-reported outcomes.

resultsOwing to difficulties in including suitable patients the enrollment phase was closed when 73 patients were randomized. Notwithstanding the lower number of patients, in the modified intention-to-treat population (n = 70) the primary endpoint was statistically significant: tremor improved after 1 week in 62.9% in Li-PR group against 20.0% of patients in Li-IR group (p = .0006; two-tailed Fisher's exact test). The difference remained statistically significant after 4 (p = .0031) and 12 weeks (p = .0128). The same analysis performed in the PP population confirmed these results. Among the secondary endpoints, only the factor convenience of the treatment satisfaction questionnaire showed a statistically significant difference between groups. There were no apparent differences in the safety profile of the two formulations.

conclusionsThis study is the first comparative documentation of a potential benefit of the prolonged-release formulation in reducing the symptom tremor, a well-known adverse effect of lithium therapy. Indeed, the study results should be interpreted taking into account the sample size lower than planned.

Indexed as

Bipolar DisorderLithiumDouble-Blind MethodHumansPsychiatric Status Rating ScalesTreatment OutcomeTremorLithiumbipolar disorderlithium compoundstremor

Identifiers

PMID35137572
PMCPMC8933786
OpenAlexW4210853862

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.